<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00026533</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069053</org_study_id>
    <secondary_id>UKMC-IRB-010069</secondary_id>
    <nct_id>NCT00026533</nct_id>
  </id_info>
  <brief_title>Thalidomide in Treating Patients With Thyroid Cancer</brief_title>
  <official_title>Phase II Trial of Thalidomide for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas and Medullary Thyroid Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kenneth Ain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Thalidomide may stop the growth of thyroid cancer by stopping blood flow to the&#xD;
      tumor.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness thalidomide in treating patients who have&#xD;
      thyroid cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the antitumor activity of thalidomide, in terms of tumor response and duration&#xD;
           of response, in patients with metastatic follicular, papillary, or medullary thyroid&#xD;
           carcinoma that is unresponsive to systemic radioiodine.&#xD;
&#xD;
        -  Compare the differences in antitumor activity of this drug in patients with medullary&#xD;
           carcinomas vs those with papillary or follicular carcinomas.&#xD;
&#xD;
        -  Determine the toxic effects and duration of toxic effects of this drug in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: Patients receive oral thalidomide once daily for 2 weeks and then twice daily.&#xD;
      Treatment continues for 1 year in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 50 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">November 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed follicular, papillary, insular, or medullary thyroid&#xD;
             carcinoma&#xD;
&#xD;
          -  Must meet criteria for 1 of the following:&#xD;
&#xD;
               -  Unresectable, distantly metastatic tumor that does not concentrate radioactive&#xD;
                  iodine&#xD;
&#xD;
               -  Follicular or papillary thyroid carcinoma with a large distant tumor burden that&#xD;
                  has not sufficiently responded to cumulative iodine I 131 doses exceeding 800 mCi&#xD;
&#xD;
          -  Radiographic evidence of tumor progression, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Evidence gathered over a period of at least 1 year with at least 3 separate x-ray&#xD;
                  studies, defining tumor volume&#xD;
&#xD;
               -  Similar radiographic evidence over a shorter period of time, delineating more&#xD;
                  than 30% increase in tumor volume&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 750/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10.5 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN&#xD;
&#xD;
          -  BUN no greater than 1.5 times ULN&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infection not controlled with medications&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double contraception (1 hormonal method plus 1&#xD;
             barrier method OR 2 simultaneous barrier methods) for female patients or barrier&#xD;
             contraception for male patients for more than 4 weeks prior to, during, and for at&#xD;
             least 4 weeks after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior thalidomide&#xD;
&#xD;
          -  No other concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior systemic chemotherapy&#xD;
&#xD;
          -  No concurrent systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior radiotherapy allowed&#xD;
&#xD;
          -  Concurrent limited external-beam radiotherapy to isolated sites of bony metastases&#xD;
             allowed, provided that these sites are not the sole sites of metastatic disease and do&#xD;
             not constitute the sites of evaluable disease for this study&#xD;
&#xD;
          -  No concurrent radioiodine therapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior surgery allowed&#xD;
&#xD;
          -  Concurrent surgery allowed to sites that do not constitute evaluable disease for this&#xD;
             study&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent medications that are known to increase the risk of peripheral neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Ain, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Lucille P. Markey Cancer Center at University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert B. Chandler Medical Center, University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536-0298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>November 9, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 4, 2017</last_update_submitted>
  <last_update_submitted_qc>June 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Kenneth Ain</investigator_full_name>
    <investigator_title>Sponsor/PI</investigator_title>
  </responsible_party>
  <keyword>stage IV papillary thyroid cancer</keyword>
  <keyword>stage IV follicular thyroid cancer</keyword>
  <keyword>thyroid gland medullary carcinoma</keyword>
  <keyword>recurrent thyroid cancer</keyword>
  <keyword>insular thyroid cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

